Malta, 8 April 2005
Circular No. P10/2005

Dear Healthcare Professional,

Re: Suspension of Bextra® (valdecoxib) as an interim measure

Following the recent agreement between Pfizer and the European Medicines Agency (EMEA) regarding the suspension of the use of Bextra® (valdecoxib) in Europe as an interim measure pending finalisation of the ongoing class review of COX-2 Inhibitors, the Medicines Authority would like to inform prescribers that the advice provided for Bextra® in the attached **press release** issued by the EMEA is appropriate, and that further information will be provided as it becomes available.

Medicines Authority
198, Rue D'Argens, Gzira, GZR 03 – Malta.
Tel. (+356) 23439000 Fax. (+356) 23439161 email: info.mru@gov.mt